GLIDAPA 3D 10/100/1000 SR

GLIDAPA 3D 10/100/1000 SR is an advanced triple fixed-dose combination medicine used in the management of Type 2 Diabetes Mellitus, designed for patients whose blood sugar remains inadequately controlled despite treatment with a simpler regimen, or who require a more comprehensive, multi-pathway approach to glycemic management. It brings together three modern, complementary anti-diabetic agents, each acting through a distinct mechanism:

Dapagliflozin, an SGLT2 (Sodium-Glucose Cotransporter-2) inhibitor, works in the kidneys by blocking the reabsorption of glucose back into the bloodstream, causing excess glucose to be excreted directly through urine. This mechanism is independent of insulin, which makes it a valuable addition even in patients with reduced insulin-producing capacity.

Sitagliptin, a DPP-4 (Dipeptidyl Peptidase-4) inhibitor, works by preserving the activity of incretin hormones, which help the body release insulin more effectively in response to meals while also reducing excess glucose production by the liver — with a relatively low risk of causing low blood sugar on its own.

Metformin (Extended-Release), a biguanide, reduces the amount of glucose released by the liver and improves the body's sensitivity to insulin at the cellular level. The extended-release formulation allows for steadier drug levels and generally improved gastrointestinal tolerability compared to immediate-release Metformin.

Together, these three mechanisms attack elevated blood sugar from three different biological angles — increasing glucose excretion, enhancing insulin response, and improving insulin sensitivity — offering a level of glycemic control that is often difficult to achieve with single-agent or even two-drug therapy, while simplifying the regimen into one daily tablet.

Product Information

Why GLIDAPA 3D 10/100/1000 SR Is Important

Type 2 diabetes is a progressive condition, and as it advances, many patients find that earlier treatment combinations no longer keep blood sugar adequately controlled. Persistently elevated blood glucose significantly increases the risk of long-term complications — including damage to the eyes, kidneys, nerves, and cardiovascular system — making effective, sustained control a genuine clinical priority rather than a cosmetic goal.

GLIDAPA 3D 10/100/1000 SR is clinically important because it:

• Offers three complementary mechanisms of action in one tablet, providing a comprehensive approach for patients with more advanced or harder-to-control diabetes
• The Dapagliflozin component works independently of insulin availability, making it useful even as pancreatic insulin production declines over the course of the disease
• Sitagliptin's relatively low hypoglycemia risk makes it a useful addition for patients concerned about frequent low blood sugar episodes
• Metformin ER continues to serve as a foundational therapy, improving insulin sensitivity while reducing liver glucose output
• Simplifies treatment for patients who would otherwise require three separate prescriptions, improving convenience and long-term adherence
• SGLT2 inhibitors like Dapagliflozin have also been associated in clinical literature with modest benefits for body weight and blood pressure, which are often relevant considerations in Type 2 diabetes management

Because this is an advanced triple-combination medicine spanning three distinct drug classes, it requires careful physician assessment of kidney function, cardiovascular status, and overall health before initiation, along with ongoing monitoring throughout treatment.

Key Benefits

• Triple-mechanism action — combines glucose excretion, enhanced insulin response, and improved insulin sensitivity in one tablet
• Insulin-independent glucose lowering via the Dapagliflozin (SGLT2 inhibitor) component, useful as diabetes progresses
• Low intrinsic hypoglycemia risk from the Sitagliptin component compared to some older anti-diabetic classes
• Reduces pill burden by combining three medicines into a single extended-release tablet
• Supports better long-term HbA1c and glycemic control, reducing risk of diabetes-related complications
• May offer additional benefits for body weight and blood pressure, relevant to overall metabolic health
• Extended-release Metformin component supports improved gastrointestinal tolerability
• Backed by WHO-GMP certified manufacturing, ensuring consistent tablet quality and dosing accuracy

Precautions

• Should be used only under medical supervision, with regular monitoring of blood glucose, HbA1c, and kidney function
• Caution advised in patients with kidney impairment, as both Dapagliflozin and Metformin require dose consideration based on kidney function
• The Dapagliflozin component increases urinary glucose excretion, which can raise the risk of genital and urinary tract infections — good hygiene and prompt reporting of symptoms is advised
• Should be used cautiously in patients with liver disease, heart failure, or conditions predisposing to lactic acidosis (a rare but serious risk associated with Metformin)
• Risk of dehydration or low blood pressure, particularly in elderly patients or those on diuretics, due to the fluid-related effects of SGLT2 inhibitors
• Rare risk of diabetic ketoacidosis has been reported with SGLT2 inhibitors, even with normal or mildly elevated blood sugar — any unusual nausea, vomiting, abdominal pain, or unusual fatigue should be reported promptly
• Temporary discontinuation may be required before procedures involving contrast dye (imaging scans) or major surgery — inform all treating doctors that this medicine is being taken
• Not recommended during pregnancy or breastfeeding unless specifically advised by a physician
• Alcohol should be avoided or limited, as it can increase the risk of lactic acidosis and low blood sugar
• Inform the doctor of all other medications, as several drug classes can interact with components of this combination

Side Effects

• Genital or urinary tract infections (associated with the Dapagliflozin/SGLT2 inhibitor component)
• Increased urination
• Gastrointestinal discomfort — nausea, bloating, or diarrhea (particularly with the Metformin component)
• Headache
• Nasopharyngitis (common cold-like symptoms, occasionally reported with Sitagliptin)
• Dizziness, particularly if dehydration occurs
• Metallic taste in the mouth
• Rarely: lactic acidosis (a serious condition requiring emergency care)
• Rarely: diabetic ketoacidosis, even with normal blood sugar levels — requires immediate medical attention
• Rarely: allergic skin reactions

Frequently Asked Questions

1. Where can I buy Dapagliflozin Sitagliptin Metformin online?
You can buy Dapagliflozin Sitagliptin Metformin through licensed online pharmacies or authorized pharmaceutical suppliers in India. Verify the manufacturer, strength, batch number, expiry date, and packaging before purchasing.

2. What is the price of Dapagliflozin Sitagliptin Metformin?
The price may vary depending on the brand, strengths, formulation, pack size, manufacturer, seller, taxes, and delivery charges. Check the current price with a licensed pharmacy or authorized supplier.

3. Can I order Dapagliflozin Sitagliptin Metformin online?
Yes, Dapagliflozin Sitagliptin Metformin can be ordered online where legally available. It is generally a prescription medicine, so a valid prescription may be required. Purchase only through a licensed pharmacy or authorized supplier.

4. Is Dapagliflozin Sitagliptin Metformin available from Steris Healthcare?
Availability depends on Steris Healthcare's current product range and stock status. Contact Steris Healthcare or an authorized distributor to confirm the available strengths, formulation, pack size, price, and ordering details.

5. What is Dapagliflozin Sitagliptin Metformin used for?
Dapagliflozin Sitagliptin Metformin is used to help control blood glucose levels in adults with type 2 diabetes mellitus, along with a suitable diet and regular physical activity. The three medicines work through different mechanisms to improve blood sugar control.

6. What is the composition of Dapagliflozin Sitagliptin Metformin?
Dapagliflozin Sitagliptin Metformin contains three active ingredients: Dapagliflozin, Sitagliptin, and Metformin Hydrochloride. The exact strength and formulation depend on the specific product.

7. Is a prescription required?
Yes, Dapagliflozin Sitagliptin Metformin is generally a prescription medicine and should be used under medical supervision. Your doctor will determine the appropriate strength and dosage based on your blood glucose levels, kidney function, and treatment needs.

8. How should Dapagliflozin Sitagliptin Metformin be taken?
Take Dapagliflozin Sitagliptin Metformin exactly as prescribed by your doctor. It is generally taken with food to help reduce stomach-related effects, depending on the formulation. Swallow the tablet with water and do not change the dose or stop treatment without medical advice.

9. What should I know before buying Dapagliflozin Sitagliptin Metformin?
Before buying, verify the exact strengths, formulation, manufacturer, batch number, expiry date, packaging, and storage instructions. Inform your doctor about kidney or liver problems, dehydration, recurrent urinary or genital infections, pancreatitis, pregnancy or breastfeeding, and all medicines or supplements you take.

10. How can I order Dapagliflozin Sitagliptin Metformin online?
To order Dapagliflozin Sitagliptin Metformin online, choose a licensed pharmacy or authorized supplier, select the prescribed strength and pack size, provide a valid prescription if required, verify the product and expiry details, and complete the purchase.